Kura Oncology (NASDAQ: KURA) — Perfil da empresa, notícias e dados financeiros
Kura Oncology focuses on precision medicine to develop therapies targeting various cancers.
Kura Oncology
Kura Oncology (NASDAQ:KURA) is dedicated to the research and development of new therapies aimed at treating various cancers. Specializing in precision medicine, the company seeks to identify and advance oncologic drugs that have the potential to improve outcomes for patients facing this challenging disease. Their portfolio includes several projects in different stages of clinical development, focusing primarily on targeted treatments that may offer significant benefits over existing therapies. Kura Oncology's objective is to continue pushing the boundaries of cancer treatment, leveraging cutting-edge science and technology to develop drugs that can provide real hope to patients and their families in need. The company operates with a strong commitment to innovation, patient care, and the advancement of oncology treatment options.
Resumo
Operações
Produtos e/ou serviços de Kura Oncology
- Tipifarnib is a farnesyl transferase inhibitor designed for the treatment of HRAS mutant head and neck squamous cell carcinomas.
- KO-2806 is a next-generation farnesyl transferase inhibitor aimed at improving safety and efficacy over prior inhibitors.
- Menin-MLL inhibitors target acute leukemias characterized by rearrangements of the MLL (Mixed Lineage Leukemia) gene.
- KO-539 is a potent, small molecule inhibitor of the menin-KMT2A (MLL) interaction, focused on acute myeloid leukemia.
- Preclinical programs are focused on developing novel therapeutics for other cancers with specific genetic mutations or alterations.
- Collaboration and licensing agreements with other pharmaceutical companies to enhance research, development, and commercialization of their pipeline.
equipe executiva do Kura Oncology
- Troy Edward WilsonChairman, CEO & President
- Kathleen FordChief Operating Officer
- Brian T. PowlChief Commercial Officer
- Jennifer FulkChief Financial Officer
- Thomas DoyleSenior Vice President of Finance & Accounting
- Francis J. BurrowsChief Scientific Officer
- Greg MannSenior Vice President of Investor Relations & Corporate Affairs
- Teresa Brophy BairChief Legal Officer & Corporate Secretary
- Roger BakaleSenior Vice President of Manufacturing & Supply Chain
- Mollie LeoniChief Medical Officer
Últimas notícias sobre a Kura Oncology
Kura reports KO-7246 diabetes research data
United StatesKura Oncology reports 50% response rate
United StatesKura Oncology positions Darlifarnib as foundational combination platform following strong Phase 1a results
United StatesKura Oncology combination shrinks solid tumors in 77% of trial patients
United StatesKura Oncology surges on initial sales of new leukemia therapy
United StatesKura Oncology combination shows robust activity in pretreated kidney cancer
United States
Principais indicadores financeiros
Resultados divulgados pela Kura Oncology, em USD.
- Cap. de mercado
- 880,7 mi
- Receita (TTM)
- 77,2 mi
- P/L
- —
- LPA (diluído, TTM)
- -3.4
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 67,5 mi | -303,6 mi | -278,7 mi | |
| 53,9 mi | -193,2 mi | -174 mi | |
| 0 | -165,8 mi | -152,6 mi | |
| 0 | -139,9 mi | -135,8 mi |